Total 497 GIST patients were involved in present study, with a median age of 60 years (range 23–90) and 55.9% was male. Stomach and small bowel were ... larger tumor size, higher mitotic rate ...
Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...
Gleevec response in GIST varies by mutational profile, with KIT-exon-11 mutation linked to better outcomes, emphasizing ...
Treatment with pimitespib was associated with stable disease in two-thirds of patients with advanced gastrointestinal stromal ...
A new study highlights the role of inflammatory biomarkers, mitotic index, and imatinib adherence in predicting survival ...
You have full access to this article via your institution. Figure 1: A family with multiple GISTs and mutation of the KIT gene.
GSK plc announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment ...
clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors. As announced previously, the acquisition includes lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback